Clinical Trials Logo

Clinical Trial Summary

Rheumatoid arthritis (RA) is a common, chronic autoimmune disease that causes joint damage and deformity associated with an increased disability risk and shortened life expectancy (1). New treatment methods have significantly improved disease control, but remission is still difficult to be achieved, so new and improved treatment and diagnostic options are needed for patients stratification and prognosis. To achieve this goal, the proposed study will be aimed at studying RA main factors' relationship. The project's central theme is that microbial dysbiosis is a critical determinant of RA pathogenesis, and the interaction between human factors and the microbiome contributes to the disease risk and it's activity.


Clinical Trial Description

The microbiome plays a fundamental role in diseases and human health. Technological advances in recent decades have expanded our understanding of microbes and their ability to form innate and acquired human immune responses. Advances in understanding the microbiome's impact on human immunity, along with the realization that inflammatory processes underlie a number of common diseases, including RA, necessitates an interdisciplinary approach to studying the interaction of humans and microbes at various levels. Modern sequencing technologies and new tools development for analyzing metagenomic data allow us to understand better the complex relationship between the dynamic microbes community inhabiting mucous tissues and the human immune system. Such analysis is especially relevant in Central Asia, since the investigators not only identified ethnic differences in risk loci, but also found that the composition of the intestinal and oral microbiota of Kazakhs is unique and significantly differs from the corresponding microbiota in other world regions, due to lifestyle factors characteristic of Kazakhstan and common to the whole Central Asia. The main research's purpose is to study the complex relationship between microbiome dysbiosis, local and systemic inflammation in relation to RA pathogenesis and the disease activity in the Kazakhstan population. The investigators assume that patients with RA have greater dysbiosis (local microbiota violation) in the intestine and oral cavity compared to the control group, and that it is due to a greater inflammatory response and disease activity. To consider this hypothesis, microbiome biomarkers of the oral cavity and gut in RA will be identified, RA patients immunological parameters in blood, stool and saliva samples will be analyzed, an dynamics assessment of the microbiome and immunological profile against the probiotic therapy background and an analysis of the relationships between microbiome and immunological profiles will be carried out. The research's scientific novelty and significance consist in the study of the local and general immune status in combination with the microbiomes of the oral cavity and gut in RA. The results are likely not only to give a new insight into the relationship between human factors and pathogenic factors, but may also affect the RA diagnosis, the disease activity prognosis and inform preventive strategies. Thus, a better understanding of the complex microbial interactions with the immune system of the mucous membrane in RA can advance our understanding of RA pathophysiology, help predict future relapses, develop strategies for prevention and early diagnosis, and lead to new therapeutic directions' development aimed at the microbiome. The results impact on the science and technology development contribute to the first comprehensive study of the RA pathogenesis in the Central Asian population. The investigators expect not only to receive important new information about the RA etiopathogenesis, but also the complex interaction that determines the pathogenesis and disease activity. The proposed study has the potential not only to improve the methods of diagnosis and monitoring of RA patients in Kazakhstan, but also can contribute to a better RA understanding in general, paving the way for personalized diagnosis and treatment of rheumatic diseases. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05777577
Study type Interventional
Source Nazarbayev University
Contact Almagul Kushugulova, Professor
Phone +7172 706498
Email akushugulova@nu.edu.kz
Status Not yet recruiting
Phase N/A
Start date March 2023
Completion date December 2024

See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4